In vitro Biological Estimation of [1,2,3]triazolo[4,5-d]pyrimidine Derivatives as Anti-breast Cancer Agent: DFT, QSAR and Docking Studies.
Clicks: 479
ID: 50530
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
65.8
/100
479 views
328 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #1 of 195 articles by views in current pharmaceutical biotechnology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 195 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
20 sets of synthesized molecular compounds were considered as anti-breast cancer agent. The molecular descriptors which describe the microbial activities of the studied compounds were calculated using B3LYP/6-31+G* and obtained. The parameters obtained were EHOMO (eV), ELUMO (eV), dipole moment (Debye), log P, molecular weight (amu), HBA, HBD, Vol and Ovality were screened. The obtained calculated descriptors were used to develop QSAR model for prediction of experimental inhibition concentration (IC50) using SPSS and Gretl software packages for multiple linear regression (MLR) and MATLAB for artificial neural network (ANN). From this statistical analysis, MLR and ANN were observed to be predictive, however, ANN-QSAR model predicted more efficiently than MLR. Furthermore, molecular docking study was executed with breast cancer cell line (PDB ID: 1hi7); it was observed that BS20 with binding energy of -7.0 kcal/mol bounded more efficiently than other compounds also, it inhibited more than the standard used (5-FU).
| Reference Key |
kolawole2019incurrent
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kolawole, Oyebamiji Abel;Banjo, Semire; |
| Journal | current pharmaceutical biotechnology |
| Year | 2019 |
| DOI |
10.2174/1389201020666190904163003
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.